MTX110
As of the edition of 20 October 2026, MTX110 is a drug known only by a code name: stopped in 2024; acts on HDAC1, HDAC10 and HDAC11 and 8 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Code name only
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
11 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product11 company-target rows are on route A because of MTX110.
See the 11 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| HDAC3 | Histone deacetylase 3 | O15379 |
| HDAC4 | Histone deacetylase 4 | P56524 |
| HDAC1 | Histone deacetylase 1 | Q13547 |
| HDAC7 | Histone deacetylase 7 | Q8WUI4 |
| HDAC2 | Histone deacetylase 2 | Q92769 |
| HDAC10 | Polyamine deacetylase HDAC10 | Q969S8 |
| HDAC11 | Histone deacetylase 11 | Q96DB2 |
| HDAC8 | Histone deacetylase 8 | Q9BY41 |
| HDAC6 | Protein deacetylase HDAC6 | Q9UBN7 |
| HDAC9 | Histone deacetylase 9 | Q9UKV0 |
| HDAC5 | Histone deacetylase 5 | Q9UQL6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biodexa Pharmaceuticals | Lead sponsor of trials | 2022 to now |